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bjectives The aim of this study was to determine the safety and efﬁcacy of a novel pimecrolimus-
luting stent in a porcine coronary model and in a phase I clinical trial.
ackground Rapamycin- and paclitaxel-eluting stents reduce the need for repeat intervention by
imiting neointimal hyperplasia but might cause delayed healing, pre-disposing patients to late stent
hrombosis. Because inﬂammation plays a key role in restenosis, pimecrolimus, an anti-inﬂammatory
rug, might reduce restenosis without adversely affecting re-endothelialization.
ethods We evaluated a novel polymeric pimecrolimus-eluting stent covered with a thin parylene
diffusion barrier in a porcine coronary model and in a phase I human clinical trial. The clinical
tudy was a prospective, nonrandomized, ﬁrst-in-human hypothesis-generating study that enrolled
5 patients who had a single de novo native coronary stenosis.
esults At 28 days and 3 months in the porcine model, histopathologic indicators predicted safety
nd biocompatibility when stents coated with polymer only, drug only, and 2 drug-polymer formu-
ations were compared with bare-metal stents (BMS). In the phase I clinical trial, 15 patients had suc-
essful implantation of pimecrolimus-eluting stents. By 6 months, no patient suffered death, myocar-
ial infarction, or stent thrombosis. However, the angiographic restenosis (61%), mean late loss (1.44
m), and repeat target lesion revascularization (53%) were signiﬁcantly higher than historical BMS
ontrols. Whereas the primary end point was percent volume obstruction, restenosis was so severe
hat operators performed intravascular ultrasound examination in only 6 patients.
onclusions Pimecrolimus-eluting stents induced an exaggerated neointimal hyperplasia at
months in comparison with historical controls. (J Am Coll Cardiol Intv 2009;2:1017–24) © 2009 by
he American College of Cardiology Foundation
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1018irst-generation drug-eluting stents (DES) eluting rapamy-
in or paclitaxel reduce restenosis and the need for repeat
arget lesion revascularization (TLR) (1,2). Unfortunately,
he nonspecific nature of these stent-based therapies likely
ontributes to delayed healing or incomplete re-
ndothelialization associated with a small increase in late
tent thrombosis (3–7). The ideal DES formulation would
imit neointimal formation without delaying healing or
ndothelialization of the stent.
See page 1025
Acute and chronic inflammation play a central role in
eointimal development, and it has thus been proposed as a
arget for prevention of restenosis (8,9). Pimecrolimus
Novartis Pharma AG, Basel, Switzerland) is a potent anti-
nflammatory compound that binds to macrophilin-12
FKBP-1) and inhibits the calcium-dependent phos-
phatase, calcineurin. It is not a
rapamycin analog, and its mecha-
nism of action is independent of
the mammalian target of rapamy-
cin (mTOR). Pimecrolimus is a
derivative of macrolactam asco-
mycin produced by the bacterium
Streptomyces hygroscopicus var. asco-
myceticus. The compound inhibits
T-cell activation by blocking of the
transcription of pro-inflammatory
cytokines. Pimecrolimus inhibits
interleukin-2, interferon gamma
(Th1-type), interleukin-4, and
interleukin-10 (Th2-type) cyto-
kine synthesis in human T cells
at nanomolar concentrations. In
addition, pimecrolimus prevents
he release of inflammatory cytokines and the mediators
rom mast cells in vitro after stimulation by antigen/IgE.
The efficacy of stent-based pimecrolimus delivery in a
orcine coronary model has been demonstrated for 2
dditional and different stent designs coated with differ-
nt stent-polymer formulations (10,11). These studies
emonstrated complete endothelialization, a reduction in
eointimal area at 28 days compared with bare-metal
tent (BMS) controls, and no histological indicators of
elayed healing. These studies supported the hypothesis
hat stent-based delivery of pimecrolimus inhibits neoin-
imal formation without delayed healing in the porcine
oronary model.
The aim of our study was to evaluate the feasibility,
afety, and efficacy of a novel pimecrolimus-eluting stent
n a porcine coronary model and in a phase I human
bbreviations
nd Acronyms
MS  bare-metal stent(s)
ES  drug-eluting stent(s)
VUS  intravascular
ltrasound
TOR  mammalian target
f rapamycin
CI  percutaneous
oronary intervention
CA  quantitative coronary
ngiography
LR  target lesion
evascularization
VR  target vessel
evascularizationlinical trial. aethods
aterials. The components of this novel anti-inflammatory
ES are a stainless steel balloon-expandable platform (Du-
aflex, Avantec Vascular, Sunnyvale, California), the drug
imecrolimus, and a nonbiodegradable polymeric diffusion
arrier designed to modulate drug release (parylene C).
The Duraflex BMS, evaluated in a Japanese prospective
egistry and in the IMPACT (Inhibition with MPA of
oronary Restenosis Trial) (12), received CE Mark ap-
roval in 2000 and is commercially available in over 30
ountries.
Pimecrolimus in a solvent was sprayed onto the stent at
oom temperature and then air-dried at 50°C for 10 h. The
ose on the stents used in the clinical trial was 400 g of
imecrolimus/stent. A parylene C diffusion barrier was
pplied to the drug coating by a chemical vapor deposition
ethod at room temperature. The total thickness of the
rug-polymer layer was approximately 3 to 4 m. The
evices were sterilized with ethylene oxide at 32°C.
Drug extraction and quantification by high-performance
iquid chromatography confirmed that no degradation of
imecrolimus occurred during the manufacturing process.
n vitro pharmacokinetic studies demonstrated release of
5% of the drug at 1 day and 35% at 7 days in a static
orcine serum infinite sink.
Retained samples of stents from the same manufacturing
ot used in the clinical trial, independently analyzed (Evans
nalytical Group, Sunnyvale, California), demonstrated
hat any trace amounts of contaminants and organic solvents
ere well below manufacturing standards (13). High-
erformance liquid chromatography demonstrated 99%
ure residual pimecrolimus without oxidative species.
reclinical studies. The histopathlogic specimens from pre-
linical studies in a porcine coronary model were indepen-
ently analyzed by a cardiac pathologist. Analysis included
ll samples from 28-day and 12-week feasibility, safety,
fficacy and toxicity overlap implants with a BMS control,
.2-m-thick polymer only, drug-only (pimecrolimus 200
g), and 2 different drug-polymer formulations (pimecroli-
us 300 g with 0.2-m barrier and pimecrolimus 400 g
ith 0.2-m barrier). Twenty-five porcine hearts with 66
tented arteries (10 pairs of overlapping stents) were im-
lanted with stents with an intended balloon/artery ratio of
.1/1. Explanted stents were examined from the 28-day
tudy. Scanning electron microscopy was conducted on 9 of
6 vessels with single stents. Eighteen hearts and 37 stented
rteries were examined at 90 days. Stented and adjacent
onstented sections were examined with established meth-
dology (14,15).
hase I clinical trial. The study was approved by the Auck-
and Ethics Committee, and each patient gave written
nformed consent before stent implantation. Patients with
ngina or documented silent ischemia and suitable coronary
l
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1019esions undergoing percutaneous coronary intervention
PCI) were enrolled between March and June 2006. The
esion to be treated was a single de novo native coronary
rtery stenosis of 50% and 100% diameter, visually
stimated to be in a vessel segment3.0 mm and3.5 mm
n diameter with a maximum length of 14 mm and
hrombolysis In Myocardial Infarction coronary flow 1.
orto-ostial lesions, unprotected left main lesions, and
esions within 2 mm of the origin of the left anterior
escending or left circumflex were excluded. Patients who
ad suffered a myocardial infarction with total creatine
inase 3 normal within the previous 72 h were also
xcluded.
linical trial design and study end points. The clinical trial
as a prospective, nonrandomized, consecutive enrollment
egistry carried out at 2 sites in Auckland, New Zealand.
he goal was to evaluate the safety and potential inhibition
f neointimal thickening by pimecrolimus eluted from the
vantec Duraflex drug-eluting stent at 6 months through
linical, angiographic, and intravascular ultrasound (IVUS)
nd points.
The primary end point was percent volume obstruction
ssessed by IVUS at 6 months. Secondary end points were
ajor adverse cardiac events (MACE) at 1, 6, 9, and 12
onths. A MACE was defined as death, Q-wave MI,
on–Q-wave MI, and revascularization by surgery or PCI
ttributed to the target lesion. Additional secondary end
oints were acute success, TLR, and target vessel revascu-
arization (TVR) at 1, 6, 9, and 12 months. Angiographic
nd points were binary restenosis and in-stent late lumen
oss at 6 months.
tatistical analysis. PRE-CLINICAL STUDY. Normality of data
as tested with the Shapiro-Wilk test. Measurements
f artery size and percent stenosis were reported as mean
SD. Injury score and inflammation are reported as
edian and interquartile range due to their skewed distri-
ution. Analysis of variance was used to assess differences in
tenosis severity and artery measurements in the 5 test
roups. The F test and post-analysis of variance Tukey
onestly Significant Difference test were used for the
airwise comparisons. Kruskal-Wallis tests were used to
Table 1. Summary of Vessel Histomorphometry for 47 Single Stents at 28
BMS Drug Only
Dru
Artery (mm2) 9.93 0.93 8.93 1.92
Lumen (mm2) 5.20 0.97 4.75 1.27
Neointima (mm2) 2.65 0.66 2.19 1.26
Area stenosis (%) 33.96 8.62 30.58 14.14 3
Injury score 0.33 (0.33–1.00) 0.67 (0.00–1.00) 0
Inﬂammation score 1.00 (0.67–1.00) 0.67 (0.33–1.33) 0
Values are mean SD or median (interquartile range). All were analyzable.BMS bare-metal stent(s).ssess if there were differences in average injury and inflam-
ation scores across groups.
LINICAL STUDY. This was a first-in-human pilot study
esigned to obtain preliminary observations and generate
ypotheses for future studies. As such the sample size was
ot calculated on the basis of an end point hypothesis but to
rovide information on device efficacy and safety. The
ean, SD, and 95% confidence intervals were determined
or continuous variables, and results were compared with
reviously published findings with the BMS Duraflex (12)
n similar patient and lesion populations. To assess whether
he mean parameters of the current samples were signifi-
antly different from means of these parameters from
istorical controls, 1-sample t tests were applied.
rocedure. Stenting was carried out in the standard manner
t each center, with either heparin or bivalirudin anticoag-
lation. The patients were pretreated with aspirin, and those
ot pretreated with clopidogrel received a 600-mg loading
ose at the time of the procedure. Aspirin was administered
fter the procedure for at least 1 year, and clopidogrel was
dministered for at least 3 months.
linical study management. The pre-clinical specimens
ere analyzed by the Biomedical Research Foundation of
outh Texas.
For the clinical trial, the IVUS and quantitative angio-
raphic (quantitative coronary angiography [QCA]) core
aboratory was the Stanford Cardiovascular Core Analysis
aboratory, Stanford University, Palo Alto, California.
ata management was by Nextrials, San Ramon, Califor-
ia. Study monitoring was conducted by the clinical regu-
atory unit of Avantec Vascular Corporation. There was an
ndependent Clinical Events Committee.
esults
re-clinical studies. Table 1 summarizes the results of vessel
istomorphometry at 28 days. Although the mean neointi-
al area of the 400-g pimecrolimus-eluting stents (1.50
.42 mm2) was significantly less than bare-metal controls
2.65  0.66 mm2) and polymer only (2.17  0.86 mm2)
tents, vessel areas were also significantly different (7.68 
in a Porcine Coronary Model
g With
mer
Drug 400 g With
Polymer Polymer Only p Value
2.00 7.68 1.20 9.46 1.50 0.04
1.87 4.52 0.79 5.30 1.38 0.49
0.74 1.50 0.42 2.17 0.86 0.06
12.00 25.04 6.03 29.71 12.13 0.35
0–1.33) 0.33 (0.17–0.84) 0.33 (0.00–0.67) 0.84
3–1.00) 0.33 (0.33–0.67) 0.33 (0.00–0.67) 0.24Days
g 300
Poly
9.91
5.05
2.60
5.12
.67 (0.0
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1020.20 mm2 vs. 9.93  0.93 mm2) for 400-g pimecrolimus
nd BMS controls, respectively. This resulted in a nonstatis-
ically significant percent area stenosis for the 400-g
imecrolimus-eluting stents (25.0  6.0) compared with
MS (34.0  8.6) and polymer-only (29.7  12.1) stents.
he mean neointimal area and percent area stenosis were
imilar for the polymer-only, 200-g drug-only, and the
00-g pimecrolimus-polymer–coated stents as compared
ith BMS. The vessel injury (range 0.5 to 0.8) and
nflammation (range 0.5 to 0.9) scores were similar and low
or all study groups. Inflammatory cells consisted of pre-
ominantly tissue macrophages and foreign body giant cells.
ecrotizing (n  2) and non-necrotizing (n  3) granu-
oma were noted in only 5 of 47 specimens (10.6%) for the
ingle stents (BMS, n  1; polymer only, n  3; drug-only,
 1; 300-g drug-polymer, n 0; 400-g drug-polymer,
 0). Residual intimal fibrin scores were low and similar
or all groups (range 0.1 to 0.2). Endothelialization scores
ere high (3.0 or complete for all groups). The 9 samples
ubmitted for SEM showed patent lumens with the luminal
urface fully covered by mature cobblestone or elongated
ndothelial cells. Figure 1 shows a representative his-
Figure 1. Neointimal Growth and Injury Following a Pimecrolimus Stent Imp
(A) Low-power section showing neointimal growth and injury in a pimecrolim
injury is greater and media is absent due to vessel stretch. (B) Higher-power s
injury.
Table 2. Summary of Histomorphometry for 35 Single Stents at 12 Weeks
BMS Drug Only
Dru
Artery (mm2) 7.17 1.34 7.30 1.01
Lumen (mm2) 4.51 0.86 4.66 0.58)
Neointima (mm2) 1.14 0.28 1.11 0.35)
Area stenosis (%) 20.47 4.35 19.05 5.10
Injury score 0.00 (0.00–0.33) 0.00 (0.00–0.33) 0
Inﬂammation score 0.00 (0.00–0.33) 0.00 (0.00–0.00) 0
Values are mean SD or median (interquartile range). All were analyzable.BMS bare-metal stent(s).opathologic image of a porcine coronary artery treated with
he pimecrolimus stent at 28 days. A modest amount of
eointimal thickening occurred in regions of vascular injury.
Table 2 summarizes the results of vessel histomorphom-
try at 12 weeks. The mean neointimal area and percent area
tenosis were similar for the polymer-only, 200-g drug-
nly, and the 300- and 400-g pimecrolimus-polymer
oated stents as compared with BMS. The injury (range 0.1
o 0.4) and inflammation (range 0.1 to 0.2) scores were
imilar and low for all study groups. Tissue macrophages
nd occasional multinucleated foreign body giant cells were
dentified without necrotizing granuloma. Residual intimal
brin was not detected in any of the study groups (fibrin
core 0). Endothelialization scores were similar for all
roups (range 2.43 for BMS controls, 3.0 or complete for
olymer-only, 200-g drug, and 400-g drug-polymer). In
few cases, the pathologist observed artificial sloughing of
ndothelial cells due to tissue processing, which might have
ontributed to lower endothelial scores.
linical results. Patient demographic data are shown in
able 3, and lesion characteristics are shown in Table 4.
hese were simple lesions, with 80% classified as American
tion
nt. More neointima has formed across the top portion of this vessel, where
showing a moderate neointimal growth at a region of higher vascular
orcine Coronary Model
g With
mer
Drug 400 g With
Polymer Polymer p Value
 1.16 7.26 0.79 7.08 1.03 0.63
 0.75 4.31 0.61) 4.19 0.57 0.52
 0.44 1.38 0.43 1.44 0.45 0.45
 5.51 24.21 6.89 25.28 6.06 0.21
0–0.33) 0.33 (0.00–0.67) 0.00 (0.00–0.33) 0.21
0–0.33) 0.33 (0.00–0.33) 0.00 (0.00–0.33) 0.18lanta
us ste
ectionin a P
g 300
Poly
7.70
4.77
1.18
19.57
.00 (0.0
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1021eart Association/American College of Cardiology type A
Table 4). Device success was 100%, with the pimecrolimus-
luting stent being successfully delivered and deployed in all 15
atients. No additional stents were implanted.
In-hospital and 30-day MACE was only a single TLR by
CI. By 6 months there were no myocardial infarctions,
tent thromboses, or deaths, but 7 of the 13 (54%) had
epeat TVR.
Table 5 shows angiographic findings at baseline and
ollow-up for those patients who received a pimecrolimus-
luting stent and compares these with patients in the Duraflex
Table 3. Patient Demographic Data (n  15)
Age, mean yrs (range) 59 (44–74)
Male 8 (53)
Cigarette smoking
Current smoker 3 (20)
Former smoker 6 (40)
Never smoked 6 (40)
Dyslipidemia 15 (100)
Hypertension requiring medication 8 (53)
Diabetes mellitus 2 (13)
Family history of coronary artery disease 12 (80)
Previous MI 4 (27)
Worst CCS angina class
I 3 (20)
II 7 (47)
III 0 (0)
IV 2 (13)
Unstable 3 (20)
Values are n (%) unless otherwise indicated.
CCS Canadian Cardiovascular Society; MImyocardial infarction.
Table 4. Lesion Characteristics (n  15)
Coronary artery
Right 6 (40)
Anterior descending 6 (40)
Circumﬂex 3 (20)
TIMI ﬂow before
0 0
1 0
2 1 (7)
3 14 (93)
Thrombus present 0
Calciﬁcation
Little/none 12 (80)
Moderate/severe 3 (20)
AHA/ACC lesion type
A 12 (80)
B1/B2 3 (20)
C 0
Values are n (%).
AHA/ACCAmericanHeartAssociation/AmericanCollegeofCardiology; TIMIThrombolysissIn Myocardial Infarction.MS control arm of the Impact trial. (12) One patient
eclined angiographic follow-up, and another was lost to
ollow-up. Although patients receiving the pimecrolimus-
luting stent had shorter lesions in larger vessels than historical
MS controls, outcomes were significantly worse (Table 5). At
ngiographic follow-up, the in-segment restenosis rate of
1.5% and the in-stent late loss of 1.44 mm were significantly
p  0.01 and p  0.05) greater than BMS controls (26.5%,
.91 mm, respectively).
Angiographic frames before and after stenting and at
ollow-up for the 8 patients with restenosis are shown in
igure 2.
The IVUS results (Table 6) are biased toward those
atients with less severe restenosis, because IVUS record-
ngs were made in only 6 patients because the operators
ere unwilling to make IVUS recordings in patients with
evere restenosis.
iscussion
he main findings of the pre-clinical porcine study and the
hase I first-in-human trial of a novel pimecrolimus-eluting
tent are that pre-clinical testing suggested pimecrolimus
Table 5. Baseline, Post-Procedure, and Follow-Up Angiographic Results
Pimecrolimus
(n  15)
BMS
(n  50) p Value*
Baseline
Lesion length, mm 6.22 1.93 11.80 3.95 0.001
MLD, mm 1.00 0.48 0.79 0.43 0.14
DS, % 65 15 71.6 15.6 0.14
Reference vessel diameter, mm 2.86 0.55 2.72 0.47 0.38
Post-procedure
In-lesion MLD, mm 2.37 0.57 2.20 0.37 0.30
In-stent MLD, mm 2.76 0.43 2.56 0.40 0.12
In-lesion DS, mm 20.4 15.4 19.5 14.0 0.84
In-stent DS, mm 7.1 13.6 7.9 11.2 0.84
Pimecrolimus
(n  13)
BMS
(n  50) p Value*
6-month follow-up
In-lesion MLD, mm 1.23 0.73 1.66 0.59 0.06
In-stent MLD, mm 1.33 0.73 1.72 0.65 0.08
In-lesion DS, % 57.2 22.2 40.9 19.0 0.02
In-stent DS, % 53.9 22.0 39.0 20.8 0.03
In-lesion late loss, mm 1.12 0.90 0.91 0.49 0.42
In-stent late loss, mm 1.44 0.89 0.85 0.55 0.03
In-lesion binary restenosis, mean 61.5 26.5 na
In-stent binary restenosis, mean 53.8 26.5 na
Values aremean SD or %. Baseline, post-procedure, and follow-up angiographic results for the
patients who received a pimecrolimus-eluting stent compared with historical bare-metal stent
(BMS) controls from the IMPACT trial (12). *One-sample t test compared with the expectedmean
from historical control.
DS diameter stenosis; MLDminimum lumen diameter.tents were safe but did not predict the exaggerated neoin-
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1022imal response seen in patients. Nothing in the pre-clinical
tudy suggested efficacy. In fact there was no apparent
eduction in inflammation evident from pre-clinical evalu-
tion, a finding that might have predicted the lack of
fficacy. Interestingly, the drug is only approved for topical
se, and little is known about its application in the coronary
rtery. Although this drug has efficacy topically, it might not
Figure 2. Cine Frames From the 8 Patients Who Had Restenosis by 6 Mon
(A) Before stenting, (B) after stenting, and (C) at follow-up.
Table 6. IVUS Findings After Pimecrolimus Stent Implantation and
at Follow-Up
IVUS Analysis Post-Stent 6-Month
Change in in-stent minimum lumen area,
mm2 (n  8)
7.6 1.9 3.8 2.7
Neointimal volume index, mm3/mm (n  6) 3.4 1.4
Percent neointimal volume (NIH volume/
stent volume), % (n  6)
39.8 16.6
Vessel volume index 15.6 3.4 15 3.9
Plaque volume index 6.8 3.2 6.4 3.3
Lumen volume index 9.5 1.7 5.7 2.9
Vessel volume index 16.8 4.1 15.2 4.8
Plaque volume index 8.4 4.0 9.3 5.7
Lumen volume index 10.6 4.9 8.5 5.8
Vessel volume index 12.9 5.0 11.2 4.3
Plaque volume index 4.5 3.0 5.3 3.2
Lumen volume index 8.4 2.4 5.9 1.3
Values are mean  SD. *One-sample t test compared with the expected mean of the historical
control.EIVUS intravascular ultrasound; NIH in-stent neointimal hyperplasia.ave similar efficacy in human coronary arteries. Alterna-
ively, the hypothesis that inflammation is an important
echanism of restenosis might be incorrect, and yet another
ossibility is that the drug dose was incorrect.
Endothelialization in the juvenile porcine model occurs
apidly and is usually completely different from man. Pre-
ious pre-clinical studies showed similar endothelialization
etween Cypher and BMS (15), yet it did not predict the
ndings in man (16).
In the clinical trial, neointimal formation was greater
ith the 400-g pimecrolimus-eluting polymeric stent than
n historical BMS controls (Table 5). The in-stent late loss
f 1.44 mm and the angiographic binary restenosis of 61.5%
ere significantly higher than with historical control pa-
ients (0.85 mm and 26.5%, respectively). Target vessel
evascularization and TLR were more common (63%) than
n control patients (12%).
It is not readily apparent why the pimecrolimus-eluting
tent had outcomes that were worse than historical BMS
ontrols (Table 5). Although the pre-clinical studies might
ot have identified efficacy, they did not identify the
xaggerated neointimal response. In general, animal models
re reported to predict human responses, but results of this
rial confirm that clinical efficacy and safety can only be
roven in humans (17,18).
The GENESIS (Randomized, Multicenter Study of the
imecrolimus-Eluting and Pimecrolimus/Paclitaxel-thsluting Coronary Stent System in Patients with De Novo
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1023esions of the Native Coronary Arteries) trial (19) that
mployed pimecrolimus—but released from a bioabsorbable
olymer in reservoirs on a different stent platform—had
linical results that were remarkably similar to those from
ur trial (Table 7). In pre-clinical porcine studies for the
ENESIS trial, pimecrolimus released from this platform
eemed safe and efficacious (11). The GENESIS trial,
erminated early, randomized 249 patients to receive a
eservoir stent (Conor Medical, Menlo Park, California)
eleasing pimecrolimus alone, pimecrolimus plus paclitaxel,
r paclitaxel alone. Results for patients in the pimecrolimus
rm were remarkably similar to those in our trial, with
n-stent late loss in the order of 1.4 mm and with more than
ne-half the patients suffering restenosis (Table 7). More
han one-half of our patients and more than one-third of
atients receiving the pimecrolimus-only stent in the GEN-
SIS trial had TVR. Those GENESIS trial patients receiv-
ng stents with co-elution of a smaller dose of pimecrolimus
n addition to paclitaxel had less late loss, restenosis, and
LR than pimecrolimus alone but more than those patients
eceiving stents that released paclitaxel alone. Pre-clinical
orcine studies had failed to predict the exaggerated intimal
yperplastic response, as in our study. Pimecrolimus is the
ikely cause of the adverse outcomes, because it is the
ommon factor in the 2 trials that employed different stent
latforms and polymers.
In a third pre-clinical study (10), metal stents of a
ifferent design eluting different doses of pimecrolimus
rom an absorbable polymer (Biotronik, Berlin, Germany)
eemed safe and efficacious. A clinical trial using this
imecrolimus-eluting stent has completed enrollment, and
e await the results.
The release of pimecrolimus from our trial stent was
ontrolled by a barrier layer of Parylene C applied over the
rug-coated stainless steel stent. Parylene C has been widely
sed for over 10 years on medical implants such as pace-
akers, implantable defibrillators, and pacing wires. It is a
omponent of coatings on a number of DES, including the
ypher sirolimus-eluting stent (Johnson and Johnson, Mi-
mi, Florida), and on the PLA-Biolimus A9-eluting stents
Biosensors International, Inc., Singapore) (20).
Agents aimed at inhibiting coronary restenosis by target-
ng the inflammatory response after PCI, although prom-
Table 7. 6-Month Angiographic Follow-Up Results for Patients in the
GENESIS Trial
Paclitaxel
(n  49)
Paclitaxel and
Pimecrolimus
(n  97)
Pimecrolimus
(n  100)
Late loss in stent, mm 0.58 0.58 0.96 0.73 1.4 0.67
Binary restenosis in-lesion, % 7.1 24.2 51.6
Target vessel revascularization, % 2 14.4 35.5
Six-month angiographic follow-up results for patients in the GENESIS trial (18) receiving reservoirpstents that eluted paclitaxel alone, paclitaxel and pimecrolimus, and pimecrolimus alone.sing in pre-clinical studies, have produced disappointing
nd at best mixed clinical results (20–25). The pre-clinical
nd clinical outcomes with systemic as well as stent-based
mmunosuppressive therapies provide an intriguing analogy
o the dichotomous data with the pimecrolimus-eluting
tent (21–24).
The vascular pharmacodynamics of a stent-based therapy
epend on potential cell-specific responses to a particular
ompound influenced by the anatomical substrate and
henotypic expression of cellular components integral to the
iological effects of the drug.
In pre-clinical models, safety and efficacy are determined
n normal animal coronary arteries with a homogenous
mooth muscle cell population. Atherosclerotic plaque-
erived smooth muscle cells have distinct phenotypes in
omparison with medial-derived smooth muscle cells
25). Furthermore, the anatomical substrate as well as
mooth muscle cell phenotype can be variable, depending
n the type of atherosclerotic plaque (lipid-rich, fibrotic,
alcific) (26).
In human clinical trials, polymeric slow-release
apamycin-eluting stents consistently demonstrate a 90%
eduction in neointimal hyperplasia in comparison with
MS (1). Others have demonstrated that the abundance of
KBP-12, an intracellular receptor for sirolimus integral to
inding with mTOR to form the biologically active com-
lex, varies with smooth cell phenotype and is upregulated
y vascular injury (27). Normal medial smooth muscle cells
ave a low abundance of FKBP-12 in comparison with
laque-derived and neointimal smooth muscle cells. To-
ether these data support the concept that the biological
ffects of polymeric slow-release sirolimus-eluting stents
epend in part on the arterial substrate and perhaps smooth
uscle cell phenotype.
Our data suggest, given the proven biocompatibility of
he stent and polymer, a possible species or vascular
ubstrate-dependent response to pimecrolimus resulting in
nduction rather than inhibition of neointimal formation in
atients with focal de novo atherosclerotic lesions. Further
n vitro and in vivo research might help to elucidate
otential biological mechanisms for the exaggerated neoin-
imal response observed in this phase I clinical trial with
imecrolimus-eluting stents.
tudy limitations. The porcine model creates vascular in-
ury, and the method of assessment of the injury and its
onsequence has limitations.
onclusions
n this phase I clinical trial, pimecrolimus-eluting stents
nduced an exaggerated intimal hyperplasia at 6 months in
omparison with historical controls. Traditional pre-clinical
tudies predicted correctly the lack of efficacy but did not
redict the exaggerated neointimal response. The under-
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1024tanding, development, and validation of novel in vitro and
n vivo pre-clinical models are imperative to enable future
nnovation of stent-based therapies for the prevention of
estenosis.
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